BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues

Bristol Myers Squibb on Friday reported strong second-quarter results, led by the blood thinner Eliquis and cancer therapy Opdivo, as it looks to cut $1.5 billion in costs by 2025.